Accessibility Menu
Bonus BioGroup logo

Bonus BioGroup(OTC) BBIXF

Market Cap$93.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-38%
5 Year-80%
1 Year+33%
1 Month-27%
$0.08
+0.00%
+0.00Today
Bonus BioGroup last closing stock price
MetricPriceDate
Last closeUSD 0.082026-08-07
Bonus BioGroup stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.082026-07-30
1 month-27.27%USD 0.112026-06-24
3 month-42.86%USD 0.142026-05-07
Year to date+0%USD 0.082025-12-10
1 year+33.33%USD 0.062025-08-07
3 year+300%USD 0.022023-07-25
5 year-80.49%USD 0.412021-08-06
Since inception-37.79%USD 0.132019-07-30

Bonus BioGroup Financials at a Glance

Market Cap

$93.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

₪0.00

Net Income (TTM)

-₪24.49M

EPS (TTM)

-$0.01

P/E Ratio

-13.11

Dividend

$0.00

Beta (Volatility)

15.77 (High)

Price

$0.08

Volume

160

Open

$0.08

Previous Close

$0.08

Daily Range

$0.08 - $0.08

52-Week Range

$0.00 - $0.15

Estimated Earnings Date

Aug 7, 2024

BBIXF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bonus BioGroup

Bonus Biogroup Ltd. is a clinical-stage biotechnology company focused on developing innovative products based on tissue engineering and cell therapy. The company is advancing treatments for bone tissue regeneration and addressing severe conditions such as COVID-related pneumonia.

Products and Services
  • BonoFill for bone tissue regeneration in maxillofacial and orthopedic applications
  • MesenCure for treating COVID patients with pneumonia and ARDS
  • Research on therapies for chronic kidney diseases and osteoarthritis
Growth Outlook
  • Phase II clinical trials for BonoFill show promising results in bone regeneration
  • MesenCure is in Phase III trials, indicating strong potential for market entry
  • Expanding research into additional inflammatory conditions may enhance product pipeline
Financial Highlights
  • Recent quarterly net income reported at -$5.91 million, reflecting ongoing R&D investments
  • Trailing twelve months (TTM) revenue remains at $0, indicating a focus on development
  • Cash and short-term investments totaled $228,000, highlighting liquidity challenges
Bonus Biogroup Ltd. operates in a highly specialized sector, focusing on innovative solutions for significant medical challenges. The company's commitment to research and development is evident in its ongoing clinical trials, which may pave the way for future revenue streams. Despite current financial challenges, the potential for growth in the biotechnology field remains substantial, particularly with advancements in therapies that address critical health issues. Investors may find the company's trajectory and product pipeline worth monitoring as it navigates the complexities of clinical development and market entry.
AI Generated • Aug 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

49

CEO

Shai Meretzki, PhD

Website

www.bonusbiogroup.com

Headquarters

Haifa, HA 3190501, IL

BBIXF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

667.39%

Return on Capital

-699.94%

Return on Assets

-158.60%

Earnings Yield

-7.63%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$93.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.17B

Volume

160

Avg. Volume

211.905

Financials (TTM)

Gross Profit

₪0.00

Operating Income

-₪23.76M

EBITDA

-₪22.22M

Operating Cash Flow

-₪14.93M

Capital Expenditure

-₪12.00K

Free Cash Flow

-₪14.95M

Cash & ST Invst.

₪228.00K

Total Debt

₪8.90M

Bonus BioGroup Performance Analysis

Bonus BioGroup annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31ILS 0N/A
20232023-12-31ILS 0N/A
20242024-12-31ILS 0N/A
20252025-12-31ILS 0N/A
Bonus BioGroup sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31N/A
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Bonus BioGroup annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31ILS -0.02-61.6%
20232023-12-31ILS -0.01-32.4%
20242024-12-31ILS -0.01-4.0%
20252025-12-31ILS -0.01-11.7%
Bonus BioGroup sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-13.8%
Q22025-06-30N/A
Q32025-09-3044.0%
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

₪0.00

N/A

Gross Profit

₪0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$93.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.23M

N/A

Employees

42

N/A

Net Income

-₪5.91M

-0.9%

EBITDA

-₪5.67M

-13.7%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

₪228.00K

-96.7%

Total Debt

₪8.90M

-12.7%

Accounts Receivable

₪0.00

N/A

Inventory

₪0.00

N/A

Long Term Debt

₪7.11M

-16.7%

Short Term Debt

₪1.79M

+7.7%

Return on Assets

-1.59%

N/A

Return on Invested Capital

-16.42%

N/A

Free Cash Flow

-₪3.45M

+22.5%

Operating Cash Flow

-₪3.44M

+22.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLCSCell Source, Inc.
$0.65+8.00%
RVXCFResverlogix Corp.
$0.08-4.88%
IPDQFImpediMed Limited
$0.00+36.36%
CLYYFCelyad Oncology S.A.
$0.28+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.61-0.02%
SPCXSpace Exploration Technologies
$146.23+0.04%
IPSTIp Strategy
$7.39+2.36%
NVDANvidia
$225.01-0.00%

Questions About BBIXF

What is the current price of Bonus BioGroup?

Bonus BioGroup is trading at $0.08 per share.

What is the 52-week range for Bonus BioGroup?

Over the past 52 weeks, Bonus BioGroup has traded between $0.00 and $0.15.

How much debt does Bonus BioGroup have?

As of the most recent reporting period, Bonus BioGroup reported total debt of ₪2.80M.

How much cash does Bonus BioGroup have on hand?

Bonus BioGroup reported ₪1.88M in cash and cash equivalents in its most recent financial results.

What is Bonus BioGroup’s dividend yield?

Bonus BioGroup does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services